Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.

Ayoub M; Hitier C; Dehgane L; Mallet E; Tannoury M; Nemazanyy I; Roos-Weil D; Maloum K; Ringshausen I; Chapiro E; Nguyen-Khac F; Garnier D; Lagouge M; Lerner LK; Susin SA

doi:10.1038/s41375-025-02846-6

← 뒤로

Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.

Leukemia 2026 Vol.40(2) p. 449-453

Ayoub M, Hitier C, Dehgane L, Mallet E, Tannoury M, Nemazanyy I, Roos-Weil D, Maloum K, Ringshausen I, Chapiro E, Nguyen-Khac F, Garnier D, Lagouge M, Lerner LK, Susin SA

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Ayoub M, Hitier C, et al. (2026). Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.. Leukemia, 40(2), 449-453. https://doi.org/10.1038/s41375-025-02846-6

MLA Ayoub M, et al.. "Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction.." Leukemia, vol. 40, no. 2, 2026, pp. 449-453.

PMID 41501504

DOI 10.1038/s41375-025-02846-6

이 논문을 인용하기

같은 제1저자의 인용 많은 논문 (2)